Completed

CloserThe Closer Trial: A Multi-center, Prospective, Single Arm Trial to Evaluate the Safety and Efficacy of the Rex Medical Closer Vascular Sealing System (VSS) for the Management of the Femoral Arteriotomy After Percutaneous Endovascular Procedures

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Closer VSS

Device
Who is being recruted

Surgical Wound

+ Wounds and Injuries

From 18 to 80 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: May 2014
See protocol details

Summary

Principal SponsorRex Medical
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: May 1, 2014

Actual date on which the first participant was enrolled.

The objective of the trial is to demonstrate the safety and effectiveness of the Rex Medical Closer Vascular Sealing System (VSS) in sealing femoral arterial access sites and providing reduced times to hemostasis (TTH) compared with performance goals at the completion of diagnostic or interventional procedures performed through 5, 6 or 7 Fr procedural sheaths. This study will be considered a success (from a statistical perspective) if it meets both the Closer VSS superiority goal for the primary effectiveness analysis and the Closer VSS performance goal for the primary safety analysis.

Official TitleThe Closer Trial: A Multi-center, Prospective, Single Arm Trial to Evaluate the Safety and Efficacy of the Rex Medical Closer Vascular Sealing System (VSS) for the Management of the Femoral Arteriotomy After Percutaneous Endovascular Procedures
NCT02136004
Principal SponsorRex Medical
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

220 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 80 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Surgical WoundWounds and Injuries

Criteria

Inclusion Criteria: Pre-Op Inclusion Criteria: 1 - Acceptable candidates for an elective, non-emergent diagnostic or interventional endovascular procedure via the common femoral artery using a 5, 6, or 7 Fr introducer sheath. \- Exclusion Criteria: Pre-Operative Exclusion Criteria: 1. \- Significant bleeding diatheses or coagulopathy 2. \- Planned endovascular or surgical procedures within next 30 days 3. \- Planned ipsilateral femoral arteriotomy within next 90 days 4. \- Arteriotomy in ipsilateral groin within the past 30 days with any residual hematoma, significant bruising or vascular complication 5. \- Previous vessel closure device used in ipsilateral groin within the past 90 days 6. \- Previous vascular surgery or repair in the vicinity of the target access site 7. \- Severe peripheral vascular disease in the ipsilateral limb requiring surgical or endovascular treatment within the pervious 30 days or next 30 days 8. \- Existing nerve damage in ipsilateral limb 9. \- Extreme morbid obesity (BMI \> 4 kg/m2) Intra-operative Exclusion Criteria: 10. \- Use of a procedural sheath that is \< 5 Fr or \> 7 Fr 11. \- Difficult insertion of procedural sheath or needle stick problems at the onset of the procedure 12. \- Placement of an ipsilateral venous sheath for procedure 13. \- Procedural sheath placement either through the superficial femoral artery and into the profunda femoris artery, or placement at or distal to bifurcation of the superficial femoral artery and the profunda femoris artery 14. \- In subjects receiving unfractionated heparin, an ACT \> 350 seconds, or \> 250 seconds in the presence of a GP IIb/IIIa inhibitor 15. \- Procedures or existing medical conditions that may extend index hospitalization beyond 24 hours post-procedure 16. \- Systemic hypertension (SBP \> 180 mmHg) or hypotension (SBP \< 90 mmHg) just prior to enrollment

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Rex Medical Closer Vascular Sealing System to close femoral arteriotomy

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 12 locations

Suspended

UC Davis Medical Center

Sacramento, United StatesOpen UC Davis Medical Center in Google Maps
Suspended

Colorado Neurological Institute

Englewood, United States
Suspended

Washington Hospital Center

Washington D.C., United States
Suspended

Lafayette General Medical Center/Cardiovascular Institute of the South

Lafayette, United States
Completed12 Study Centers